Masatoshi Yamazoe

Masatoshi Yamazoe

Auto-generated profile, based on publicly available information

Masatoshi Yamazoe

Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 January 2020 in Nature Communications
Verified
Journal Article
Open access
PDF file
TTTakahiro TSUJI
Takahiro TSUJI
HOHiroaki Ozasa
Hiroaki Ozasa
WAWataru Aoki
Wataru Aoki
SAShunsuke Aburaya
Shunsuke Aburaya
TFTomoko Yamamoto Funazo
Tomoko Yamamoto Funazo
THToyohiro Hirai
Toyohiro Hirai
Despite the promising clinical efficacy of the second-generation anaplastic lymphoma kinase (ALK) inhibitor alectinib in patients with ALK-rearranged lung cancer, some tumor cells survive and eventually relapse, which may be an obstacle to achieving a cure. Limited information is currently available on the mechanisms underlying the initial survival of tumor cells against alectinib. Using patient-derived cell line models, we herein demonstrate that cancer cells survive a treatment with alectinib by activating Yes-associated protein 1 (YAP1), which mediates the expression of the anti-apoptosis factors Mcl-1 and Bcl-xL, and combinatorial inhibition against both YAP1 and ALK provides a longer tumor remission in ALK-rearranged xenografts when compared with alectinib monotherapy. These results suggest that the inhibition of YAP1 is a candidate for combinatorial therapy with ALK inhibitors to achieve complete remission in patients with ALK-rearranged lung cancer.

9 October 2018 in BMJ Open Respiratory Research
Verified
Journal Article
Open access
PDF file
MYMasatoshi Yamazoe
Masatoshi Yamazoe
HTHiromi Tomioka
Hiromi Tomioka
Introduction In 2016, an international working group proposed a revised definition and new diagnostic criteria for the acute exacerbation of idiopathic pulmonary fibrosis (AE-IPF). Based on these criteria, AE-IPF was diagnosed regardless of the presence or absence of a known trigger and categorised as triggered (T-AE) or idiopathic (I-AE) AE-IPF. However, the clinical characteristics of the newly defined AE-IPF and clinical differences between T-AE and I-AE are unresolved. Methods We retrospectively analysed 64 patients with AE-IPF (I-AE (42), T-AE (22)) admitted to our hospital over a 10- year period. Results I-AE and T-AE cases did not show differences in in-hospital and long-term outcomes (in-hospital mortality: I-AE 52.4%, T-AE 59.1%, p=0.61; long-term mortality: p=0.68). In the I-AE group, significantly more patients received corticosteroid therapy before an AE (I-AE 35.7%, T-AE 4.5%; p=0.01). Significantly more patients in the T-AE group had lung cancer (I-AE 7.1%, T-AE 59.1%, p<0.001). I-AE occurred more frequently in winter while T-AE did not show seasonality. The white blood cell (WBC) count and haemoglobin (Hb) level were independent predictors of in-hospital deaths in I-AE (WBC: OR 1.87; 95% CI 1.09 to 4.95, p=0.01; Hb: OR 0.26, 95% CI 0.04 to 0.78, p=0.01) but not T-AE. Discussion With the introduction of new criteria for AE-IPF, a retrospective study over a 10-year period showed a lack of prognostic difference between I-AE and T-AE. The WBC count and Hb level predicted in-hospital outcome in I-AE cases.

5 December 2023 in Molecular Cancer Therapeutics
Verified
Journal Article
Closed access
PDF file
TOTatsuya Ogimoto
Tatsuya Ogimoto
HOHiroaki Ozasa
Hiroaki Ozasa
TTTakahiro TSUJI
Takahiro TSUJI
TFTomoko Funazo
Tomoko Funazo
MYMasatoshi Yamazoe
Masatoshi Yamazoe
THToyohiro Hirai
Toyohiro Hirai
EGFR-tyrosine kinase inhibitors (TKI) are the first-line therapies for EGFR mutation–positive lung cancer. EGFR-TKIs have favorable therapeutic effects. However, a large proportion of patients with EGFR mutation–positive lung cancer subsequently relapse. Some cancer cells survive the initial treatment with EGFR-TKIs, and this initial survival may be associated with subsequent recurrence. Therefore, we aimed to overcome the initial survival against EGFR-TKIs. We hypothesized that yes-associated protein 1 (YAP1) is involved in the initial survival against EGFR-TKIs, and we confirmed the combined effect of EGFR-TKIs and a YAP1–TEAD pathway inhibitor. The KTOR27 (EGFR kinase domain duplication) lung cancer cell lines established from a patient with EGFR mutation–positive lung cancer and commercially available PC-9 and HCC827 (EGFR exon 19 deletions) lung cancer cell lines were used. These cells were used to evaluate the in vitro and in vivo effects of VT104, a TEAD inhibitor. In addition, YAP1 involvement was investigated in pathologic specimens. YAP1 was activated by short-term EGFR-TKI treatment in EGFR mutation–positive lung cancer cells. In addition, inhibiting YAP1 function using siRNA increased the sensitivity to EGFR-TKIs. Combination therapy with VT104 and EGFR-TKIs showed better tumor-suppressive effects than EGFR-TKIs alone, in vitro and in vivo. Moreover, the combined effect of VT104 and EGFR-TKIs was observed regardless of the localization status of YAP1 before EGFR-TKI exposure. These results suggest that combination therapy with the TEAD inhibitor and EGFR-TKIs may improve the prognosis of patients with EGFR mutation–positive lung cancer.

1 July 2019 in Respiratory Investigation
Verified
Journal Article
Closed access
HTHiromi Tomioka
Hiromi Tomioka
TWTakamasa Wada
Takamasa Wada
MYMasatoshi Yamazoe
Masatoshi Yamazoe
YYYuko Yoshizumi
Yuko Yoshizumi
CNChihiro Nishio
Chihiro Nishio
GIGakuji Ishimoto
Gakuji Ishimoto

1 November 2019 in Journal of Thoracic Oncology
Verified
Journal Article
Closed access
PDF file
MYMasatoshi Yamazoe
Masatoshi Yamazoe
HOHiroaki Ozasa
Hiroaki Ozasa
YKYoung Hak Kim
Young Hak Kim

1 December 2019 in Journal of Infection and Chemotherapy
Verified
Journal Article
Closed access
MYMasatoshi Yamazoe
Masatoshi Yamazoe
HTHiromi Tomioka
Hiromi Tomioka
TWTakamasa Wada
Takamasa Wada